Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma

Bone Marrow Transplantation

Volumn 25, Issue 9, 2000, Pages 937-942

  Valteau Couanet, D ^a   Benhamou, E ^a   Vassal, G ^a   Stambouli, F ^a   Lapierre, V ^a   Couanet, D ^a   Lumbroso, J ^a   Hartmann, O ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Busulfan; Infant; Neuroblastoma; SCT

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; THIOTEPA; VINCRISTINE;

ARTICLE; AUTOTRANSPLANTATION; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GENE AMPLIFICATION; HUMAN; INFANT; LIVER METASTASIS; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NEUROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL TIME; VOMITING;

EID: 0034062137     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702376     Document Type: Article

References (43)

1. Evans AE, D'Angio GJ, Randolp J. A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 1971; 27: 374-378.
2. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to Treatment. J Clin Oncol 1993; 11: 1466-1477.
3. Castel Sanchez V, Melero Moreno C, Garcia-Miguel Garcia-Rosados A et al. Stage 4 neuroblastoma en ninos menores de 1 ano. Ann Esp Pediatr 1997; 47: 584-590.
4. Evans AE, Chatten GJ, D'Angio GJ et al. A review of 17 IV-S neuroblustoma patients at the Children's hospital of Philadelphia. Cancer 1980; 45: 833-839.
5. Labreveux de Cervens C, Hartmann O, Bonnin F et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under 1 year of age? Med Ped Oncol 1994; 22: 107-114.
6. Bowman LC, Castelberry RP, Cantor A et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997; 89: 373-380.
7. Lampert F, Christiansen H, Terpe HJ et al. Disseminated neuroblastomas under 1 year of age: cell biology and prognosis. J Neuro-Oncol 1997; 31: 181-184.
8. Hartmann O, Rubie H, Coze C et al. Stage 4 neuroblastoma in infants: N-myc amplification (NMA) correlates with adverse outcome. SIOP XXX meeting. Med Ped Oncol 1998; 31: 267 (Abstr. P-41).
9. Matthay KK. Stage 4s neuroblastoma: what makes it special? J Clin Oncol 1998; 16: 2003-2006.
10. Katzenstein HM, Bowman L, Brodeur GM et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience. A Pediatric Oncology Group study. J Clin Oncol 1998; 16: 2007-2017.
11. Coze C, Hartmann O, Michon J et al. NB 87 induction protocol for Stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatrics Oncology. J Clin Oncol 1997; 12: 3433-3440.
12. Frappaz D, Michon J, Hartmann O et al. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 1992; 10: 1592-1601.
13. Avril M, Hartmann O, Valteau-Couanet D et al. Anti-infective prophylaxis with ceftazidime and teicoplanin in children undergoing high-dose chemotherapy and bone-marrow transplantation. Pediatr Hematol Oncol 1994; 11: 63-73.
14. Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207.
15. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
16. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
17. Valteau-Couanet D, Rubie H, Meresse V et al. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 1995; 16: 515-520.
18. Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observations of each patient. II Analysis and examples. Br J Cancer 1977; 35: 1-39.
19. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis 1978; 31: 557-560.
20. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. JR S Stat Soc A 1972; 135: 185-207.
21. Matthay KK, Harris R, Reynolds CP et al. Improved event-free survival (EFS) for autologous bone marrow transplantation (ABMT) vs chemotherapy in neuroblastoma: a phase III randomized Children's Cancer Group (CCG) study. Proc ASCO 1998; 17: 525a (Abstr. 2018).
22. Paul SR, Tarbell NJ, Korf B et al. Stage IV neuroblastoma in infants. Cancer 1991; 67; 1493-1497.
23. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 1985; 318; 111-116.
24. Look AT, Haves FA, Nitschke R et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581-591.
25. Brodeur GM, Azar C, Brother M et al. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 1999; 70: 1685-1694.
26. Rubie H, Hartmann O, Michon J et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. J Clin Oncol 1997; 15: 1171-1182.
27. Hartmann O, Valteau-Couanet D, Vassal G et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis of 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789-795.
28. Boland I, Vassal G, Morizet J et al. Busulfan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 1999; 79: 787-792.
29. Hartmann O, Valteau-Couanet D, Capelli C et al. High-dose chemotherapy with autologous bone-marrow support in neuroblastoma. Sangre 1994; 39: 168-171.
30. Hartmann O, Valteau-Couanet D, Benhamou E et al. Stage IV neuroblastoma in patients over 1 year at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide purged autologous bone marrow transplantation. Eur J Cancer 1997; 33: 2126-2129.
31. Ladenstein R, Philip T, Lasset C et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of 1 year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16: 953-965.
32. Stram DO, Matthay K, Leary M et al. Consolidation chemotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent children's cancer group studies. J Clin Oncol 1996; 14: 2417-2426.
33. Rosti G, Philip T, Chauvin F et al. European Group for Blood and Marrow Transplantation (EBMT) registry in solid tumors: 12 years of experience. Bone Marrow Transplant 1996; 17 (Suppl 1): 106 (Abstr. 469).
34. Hartmann O, Le Coroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. Ann Intern Med 1997; 126: 600-607.
35. Meresse V, Hartmann O, Vassal G et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan containing regimen followed by autologous bone and marrow transplantation: a study of 136 children. Bone Marrow Transplant 1992; 10: 135-141.
36. Essel JH, Schroeder MT, Harman GS et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. Ann Intern Med 1998; 128: 975-981.
37. Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. (published erratum appears in Bone Marrow Transplant 1996; 18: 829). Bone Marrow Transplant 1995; 16: 31-42.
38. Vassal G, Koscielny S, Challine D et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247-253.
39. Vassal G. Pharmacologically guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res 1994; 14: 2363-2370.
40. Schuler US, Ehrsam M, Schneider A et al. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 241-244.
41. Bhagwatwar HP, Phadungpojna S, Chow DS et al. Formu lation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996; 37: 401-408.
42. Valteau-Couanet D, Kalifa C, Benhamou E et al. Repeated high-dose chemotherapy (HDC) followed by stem cell transplantation (SCT) in young children with poor prognosis medulloblastoma or PNET: tolerance and efficacy. Bone Marrow Transplant 1998; 21 (Suppl. 1): 228 (Abstr. 798).
43. Bown N, Cotteril S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. New Engl J Med 1999; 340: 1954-1961.